PAUL S. FISHMAN, M.D.
Medical Practice in Baltimore, MD
License number
Maryland D22432
Category
Medical Practice
Type
Specialist
Address
Address
16 Fl. BLDG 3RD, Baltimore, MD 21201
Phone
(410) 328-4323
(410) 328-1149 (Fax)
(410) 328-1149 (Fax)
Personal information
See more information about PAUL S. FISHMAN at radaris.comName
Address
Phone
26 Dembeigh Hill Cir #4, Baltimore, MD 21210
26 Dembeigh Hill Cir, Baltimore, MD 21210
26 Dembeigh Hill Cir, Baltimore, MD 21210
419 Redwood St, Baltimore, MD 21201
Organization information
See more information about PAUL S. FISHMAN at bizstanding.comPaul S Fishman MD
419 W Redwood St, Baltimore, MD 21201
Categories:
Neurology Physicians & Surgeons, Physicians & Surgeons
Phone:
(410) 328-4323 (Phone)
Professional information
Dr. Paul S Fishman, Baltimore MD - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Neurology)
Address:
University Maryland Medical Center NEU
16 S Eutaw St, Baltimore 21201
(410) 328-5660 (Phone)
Neurology Associates
16 S Eutaw St SUITE 300, Baltimore 21201
(410) 328-5660 (Phone)
16 S Eutaw St, Baltimore 21201
(410) 328-5660 (Phone)
Neurology Associates
16 S Eutaw St SUITE 300, Baltimore 21201
(410) 328-5660 (Phone)
Certifications:
Neurology, 1983
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Hospitals:
University Maryland Medical Center NEU
16 S Eutaw St, Baltimore 21201
Neurology Associates
16 S Eutaw St SUITE 300, Baltimore 21201
University of Maryland Medical Center
22 South Greene St, Baltimore 21201
16 S Eutaw St, Baltimore 21201
Neurology Associates
16 S Eutaw St SUITE 300, Baltimore 21201
University of Maryland Medical Center
22 South Greene St, Baltimore 21201
Education:
Medical School
Johns Hopkins University School Of Medicine
Graduated: 1978
Baltimore City Hospital
Graduated: 1979
Colum Presby Med Center
Graduated: 1982
Johns Hopkins University School Of Medicine
Graduated: 1978
Baltimore City Hospital
Graduated: 1979
Colum Presby Med Center
Graduated: 1982
Chief Of Neurology At V.a. Medical Center
Position:
Chief of Neurology at V.A. Medical Center
Location:
Baltimore, Maryland Area
Industry:
Government Administration
Work:
V.A. Medical Center
-
Chief of Neurology
Education:
Yale University 1971 - 1974
PhD, Biology The Johns Hopkins University 1967 - 1971
BA
PhD, Biology The Johns Hopkins University 1967 - 1971
BA
Paul S Fishman, Baltimore MD
Specialties:
Neurologist
Address:
22 S Greene St, Baltimore, MD 21201
110 S Paca St, Baltimore, MD 21201
16 S Eutaw St, Baltimore, MD 21201
110 S Paca St, Baltimore, MD 21201
16 S Eutaw St, Baltimore, MD 21201
Education:
Johns Hopkins University, School of Medicine - Doctor of Medicine
Yale University, School of Medicine - Doctor of Philosophy
Yale University, School of Medicine - Doctor of Philosophy
Board certifications:
American Board of Psychiatry and Neurology Certification in Neurology (Psychiatry and Neurology)
Use Of Tetanus Toxin To Amplify Inadequate Voluntary Muscle Contraction Or To Improve Muscle Tone In An Animal Actively Vaccinated Against The Toxin And A Regimen For Treatment
US Patent:
2010015, Jun 24, 2010
Filed:
Feb 24, 2009
Appl. No.:
12/391662
Inventors:
Paul Fishman - Baltimore MD, US
International Classification:
A61K 39/08, A61P 25/14, A61P 21/00
US Classification:
4242391
Abstract:
A method of improving muscle movement, contraction and/or tone in an animal is provided. The method is carried out by administering tetanus toxin to the muscle of an animal has already been vaccinated against tetanus toxin. The toxin is administered in an amount sufficient to improve muscle movement, contraction and/or tone. The method may be used to treat patients with impaired muscle function, e.g due to compromise of the central nervous system (for example, due to stroke or spinal cord injury) or due to muscle atrophy (for example, due to immobilization after an injury). A regimen for dosage escalation of tetanus toxin is also provided.
Methods For Identifying Inhibitors Of Botulinum Neurotoxins
US Patent:
8093044, Jan 10, 2012
Filed:
Dec 3, 2009
Appl. No.:
12/630336
Inventors:
Randall Kincaid - Rockville MD, US
George Oyler - Baltimore MD, US
Yien Che Tsai - Frederick MD, US
Paul S. Fishman - Baltimore MD, US
George Oyler - Baltimore MD, US
Yien Che Tsai - Frederick MD, US
Paul S. Fishman - Baltimore MD, US
International Classification:
C07K 14/00, A61K 39/08, C12N 5/10
US Classification:
435325, 530324, 530333, 530350, 530300, 4242391, 435 4, 435 771
Abstract:
A system and method for identifying a botulinum neurotoxin inhibitor employing a botulinum neurotoxin substrate complex having a peptide substrate, preferably SNAP-25, a reporter domain on one side of said peptide substrate and an immobilization domain on the opposite side of said peptide substrate. The botulinum neurotoxin inhibitor is identified by its ability to decrease the relative amount of cleaved complex, detected through measuring a decrease in complex bound to a solid support. The method of the present invention also utilizes novel cells that express a botulinum neurotoxin substrate complex. The methods of the present invention are adapted for cell based screening to monitor the catalytic activity of a BoNT in living cells and to identify molecules that inhibit the catalytic activity of a BoNT in living cells. Also provided are novel stable cell lines that express the botulinum toxin substrate complex and viral vectors capable of efficiently expressing an active light chain of the BoNT within mammalian cells.
Methods For Identifying Inhibitors Of Neurotoxins
US Patent:
7632917, Dec 15, 2009
Filed:
Mar 31, 2005
Appl. No.:
11/095055
Inventors:
Randall L. Kincaid - Rockville MD, US
George Oyler - Baltimore MD, US
Yen Che Tsai - Baltimore MD, US
Paul S. Fishman - Baltimore MD, US
George Oyler - Baltimore MD, US
Yen Che Tsai - Baltimore MD, US
Paul S. Fishman - Baltimore MD, US
International Classification:
C07K 14/00, A61K 39/08
US Classification:
530300, 530324, 530333, 530350, 4242391, 435 4, 435 771
Abstract:
A system and method for identifying a neurotoxin inhibitor employing a neurotoxin substrate complex having a peptide substrate, preferably SNAP-25, a reporter domain on one side of said peptide substrate and an immobilization domain on the opposite side of said peptide substrate. The neurotoxin inhibitor is identified by its ability to decrease the relative amount of cleaved complex, detected through measuring a decrease in complex bound to a solid support. The method of the present invention also utilizes novel cells that express a neurotoxin substrate complex. The methods of the present invention are adapted for cell based screening to monitor the catalytic activity of a BoNT in living cells and to identify molecules that inhibit the catalytic activity of a BoNT in living cells. Also provided are novel stable cell lines that express the toxin substrate complex and viral vectors capable of efficiently expressing an active light chain of the BoNT within mammalian cells.
Targeted Delivery To The Brain Of Magnetically Labeled Stem Cells
US Patent:
2011007, Mar 24, 2011
Filed:
Sep 17, 2010
Appl. No.:
12/807999
Inventors:
Paul Yarowsky - Bethesda MD, US
Paul Fishman - Baltimore MD, US
Adam Puche - Ellicottt City MD, US
Paul Fishman - Baltimore MD, US
Adam Puche - Ellicottt City MD, US
International Classification:
A61K 35/12, A61P 25/00
US Classification:
424 937
Abstract:
Provided herein is a method of targeting stem cells to a specific region of the central nervous system of an individual in need of such treatment, comprising the steps of administering stem cells containing a superparamagnetic nanoparticles to said individual; and applying an external source of a magnetic field to the exterior of said individual's brain so as to advance and maneuver said stem cells. Also provided is a composition for targeting cells to a specific region of the central nervous system of an individual in need of such treatment, comprising stem cells containing a superparamagnetic nanoparticles.
Superoxide Dismutase/Tetanus Toxin Fragment C Hybrid Protein
US Patent:
5780024, Jul 14, 1998
Filed:
Jun 21, 1996
Appl. No.:
8/668381
Inventors:
Robert H. Brown - Needham MA
Paul S. Fishman - Baltimore MD
Jonathan W. Francis - Mansfield MA
Betsy A. Hosler - Melrose MA
Paul S. Fishman - Baltimore MD
Jonathan W. Francis - Mansfield MA
Betsy A. Hosler - Melrose MA
Assignee:
The General Hospital Corp. - Boston MA
University of Maryland at Baltimore - Baltimore MD
University of Maryland at Baltimore - Baltimore MD
International Classification:
A61K 3844, C12N 1500, C12N 902
US Classification:
424 944
Abstract:
Disclosed is a 68 kD recombinant hybrid protein comprising an enzymatically active Cu/Zn superoxide dismutase ("SOD-1") moiety and a tetanus toxin fragment C ("TTC") moiety, wherein the TTC moiety selectively delivers the hybrid protein into neurons, and the SOD-1 moiety retains substantial enzymatic activity, following neuronal uptake. Also disclosed are a DNA expression vector encoding the hybrid protein.
Methods For Identifying Inhibitors Of Botulinum Neurotoxins
US Patent:
2012023, Sep 20, 2012
Filed:
Jan 7, 2012
Appl. No.:
13/345691
Inventors:
Randall L. Kincaid - Rockville MD, US
George Oyler - Baltimore MD, US
Yien Che Tsai - Frederick MD, US
Paul S. Fishman - Baltimore MD, US
George Oyler - Baltimore MD, US
Yien Che Tsai - Frederick MD, US
Paul S. Fishman - Baltimore MD, US
International Classification:
G01N 21/64
US Classification:
435 772
Abstract:
A system and method for identifying a neurotoxin inhibitor employing a neurotoxin substrate complex having a peptide substrate, preferably SNAP-25, a reporter domain on one side of said peptide substrate and an immobilization domain on the opposite side of said peptide substrate. The neurotoxin inhibitor is identified by its ability to decrease the relative amount of cleaved complex, detected through measuring a decrease in complex bound to a solid support. The method of the present invention also utilizes novel cells that express a neurotoxin substrate complex. Also provided are novel stable cell lines that express the toxin substrate complex and viral vectors capable of efficiently expressing an active light chain of the BoNT within mammalian cells.
Delivery Of Therapeutics To The Brain And Spinal Cord
US Patent:
2006024, Nov 2, 2006
Filed:
Sep 4, 2003
Appl. No.:
10/526579
Inventors:
Jonathan Francis - Walpole MA, US
Robert Brown Jr - Needham MA, US
Paul Fishman - Baltimore MD, US
Robert Brown Jr - Needham MA, US
Paul Fishman - Baltimore MD, US
Assignee:
The General Hospital Corporation - Boston MA
University of Maryland, Baltimore - Baltimore MD
University of Maryland, Baltimore - Baltimore MD
International Classification:
A61K 48/00, A61K 39/08
US Classification:
424093200, 424239100, 514044000
Abstract:
The invention provides compositions and methods for the delivery of therapeutic compounds to the brain and spinal cord.